International
The Morning Science

What science found today

‹
 

Research

Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study

PLOS ·

The Brief

  • A multi-perspective modeling study assesses the economic value of gonorrhea resistance testing in the United States.
  • Ceftriaxone is the only recommended first-line (empiric) treatment for gonorrhea, and rising antimicrobial resistance in Neisseria gonorrhoeae threatens its effectiveness.
  • The study was published in PLOS Medicine on 2026-11-17 by Brooke E. Nichols, Betsy Wonderly Trainor, Grace Hampson, Yonatan H. Grad and Jeffrey D. Klausner.

Why it matters

Because ceftriaxone is the only recommended empiric therapy for gonorrhea, knowing whether resistance testing is economically worthwhile informs how clinics and health systems decide where to spend on diagnostics to preserve treatment options.

Who’s affected

  • public health officials and policymakers working on US STI control
  • clinicians and laboratories who manage gonorrhea testing and treatment

by Brooke E. Nichols, Betsy Wonderly Trainor, Grace Hampson, Yonatan H. Grad, Jeffrey D. Klausner Background Rising antimicrobial resistance in Neisseria gonorrhoeae threatens the effectiveness of existing therapies. Ceftriaxone is the only recommended first-line (empiric)…

Timeline

  1. Study published in PLOS Medicine

  2. PLOS Medicine

    Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study

How do you feel about this?

0 Comments

    Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study – The Morning Science